RNS No 9415c
PALL CORPORATION
6th July 1998



( BW)(PALL/TRANSFUSION-TECH)(PLL) Pall Corporation and Transfusion 
Technologies Corporation Enter Strategic Alliance
 
    NATICK, Mass. and EAST HILLS, N.Y.--(BW HealthWire)--July 6,
1998--Transfusion Technologies Corporation and Pall Corporation (NYSE:
PLL) have signed an agreement for Pall to provide blood collection
sets and leukocyte removal filters for use with Transfusion
Technologies' Chairside Separator(TM) automated blood collection
system.

   Transfusion Technologies' systems are designed to increase the
safety and efficiency of blood collection and its separation into red
blood cells and plasma for transfusion. Pall will manufacture the
single-use blood collection sets, which include Pall's proprietary
Nutricel(R) red blood cell preservative solution and leukocyte
reducing filters. Transfusion Technologies will supply its patented
separation chamber, the Dynamic Disk(TM).

    The companies will work together to obtain regulatory approval
for the products, which is anticipated in 1999. "Our agreement with
Transfusion Technologies is a continuation of our growing presence in
the blood banking market. It advances our mission to improve the
safety of the blood supply," said Eric Krasnoff, Chairman and CEO of
Pall Corporation.

    Thomas Headley, President and CEO of Transfusion Technologies
said, "We are delighted to have Pall as our manufacturing partner. The
quality of their bag materials, preservative solutions and leukocyte
removal filters is a great addition to our breakthrough blood
collection and separation systems."

    With annual sales over $1 billion, Pall Corporation is based in
East Hills, New York, USA and operates directly in 27 countries. Pall
Corporation provides innovative solutions to complex filtration and
separations problems in three major markets: Health Care, Aeropower
and Fluid Processing. The Company's shares are listed on the New York
Stock Exchange (PLL) and the London Stock Exchange (0668260). Further
information about Pall Corporation is available on the Company's Web
site at http://www.pall.com.

    Transfusion Technologies Corporation designs, develops, and
markets equipment and disposable sets for the processing of human
blood for transfusion to patients. The Company's systems are based on
the novel centrifuge technology called the Dynamic Disk(TM) on which
there are United States and international patents issued and pending.
Transfusion Technologies currently sells the OrthoPAT(R) orthopedic
perioperative autotransfusion system to salvage viable red blood cells
from blood lost during and after orthopedic surgery for reinfusion to
the patient. Incorporated in 1993, Transfusion Technologies has
offices in Massachusetts and Germany.

    This release contains "forward looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements
are based on current Company expectations and are subject to risks and
uncertainties which could cause actual results to differ materially.
Such risks and uncertainties include, but are not limited to,
regulatory approval, market acceptance of new technologies, economic
conditions and market demand.
 
     CONTACT:  Pall Corporation
               Jeremy Hayward-Surry
               (516) 484-5400
                         or
               Transfusion Technologies
               Kathleen Murphy or Lise Halpern
               (508) 655-2277

END

MSCUBUUAMBGRGWQ
Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Equatorial Palm Oil Charts.
Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Equatorial Palm Oil Charts.